Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead
August 08, 2023 08:00 ET
|
Cocrystal Pharma, Inc.
First dual coronavirus-norovirus oral antiviral is scheduled for Phase 1 in healthy volunteers In vitro studies show broad-spectrum activity against noroviruses including GII.4 pandemic strains ...